KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Share-based Compensation: 2009-2025

Historic Share-based Compensation for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $12.2 million.

  • Halozyme Therapeutics' Share-based Compensation fell 3.32% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.5 million, marking a year-over-year increase of 11.71%. This contributed to the annual value of $43.4 million for FY2024, which is 18.47% up from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' Share-based Compensation is $12.2 million, which was down 0.01% from $12.2 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Share-based Compensation peaked at $12.6 million during Q3 2024, and registered a low of $4.7 million during Q1 2022.
  • Moreover, its 3-year median value for Share-based Compensation was $9.9 million (2024), whereas its average is $10.5 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first declined by 3.68% in 2022, then skyrocketed by 70.75% in 2023.
  • Halozyme Therapeutics' Share-based Compensation (Quarterly) stood at $5.1 million in 2021, then spiked by 40.91% to $7.2 million in 2022, then skyrocketed by 33.79% to $9.7 million in 2023, then climbed by 18.61% to $11.5 million in 2024, then dropped by 3.32% to $12.2 million in 2025.
  • Its last three reported values are $12.2 million in Q3 2025, $12.2 million for Q2 2025, and $10.7 million during Q1 2025.